November 18, 2022 11:26 AM EST

FDA hits Iovance with one more delay for TIL therapy, extending BLA filing until 2023

Amber Tong

Iovance Biotherapeutics is once again pushing back its filing plans for its cell therapy — the latest in a three-year streak of delays — although execs say …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA hits Iovance with one more delay for TIL therapy, extending BLA filing until 2023

Amber Tong

Sign up to read this article for free.

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Sofinnova outlines $550M fund after IPOs and M&A deals

CMS explains what went into its first round of drug price negotiations

FDA hits Io­vance with one more de­lay for TIL ther­a­py, ex­tend­ing BLA fil­ing un­til 2023

Amber Tong

Sign up to read this article for free.

more like this

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA hits Iovance with one more delay for TIL therapy, extending BLA filing until 2023

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Sofinnova outlines $550M fund after IPOs and M&A deals

CMS explains what went into its first round of drug price negotiations